Annexin Pharmaceuticals: Green light to start phase IIa study - Redeye
Bildkälla: Stockfoto

Annexin Pharmaceuticals: Green light to start phase IIa study - Redeye

Redeye comments on Annexin Pharmaceuticals’ approval to start the phase IIa study in diabetic retinopathy (DR) and retinal vein occlusion (RVO).

Redeye comments on Annexin Pharmaceuticals’ approval to start the phase IIa study in diabetic retinopathy (DR) and retinal vein occlusion (RVO).
Börsvärldens nyhetsbrev